KKalpana Inds. (526409)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 64.25% indicates strong demand and successful volume expansion.
• Latest quarter sales of ₹11 Cr imply annualized revenue around ₹44 Cr, giving a price-to-sales ratio of roughly 3x, not extreme for a small chemical player.
• Positive book value of ₹3.69 per share provides a modest tangible asset floor.
• Debt/Equity reported as N/A suggests the company may be carrying little to no leverage, though this is unconfirmed.

Concerns

• Valuation is rich: P/E of 65.68 and P/B of 3.79 with ROE of only 3.04% and ROCE of 2.68%.
• Profit growth is flat at 0.00% and latest quarter net profit is ₹0 Cr despite 64% sales growth, indicating severe margin pressure.
• Piotroski F-Score of 4/9 points to weak operational and financial health.
• No dividend yield (0%) means investors rely solely on uncertain capital gains.

AI Analysis

I approach KKalpana Inds. with considerable caution. At ₹13.98, the market capitalizes this specialty chemical firm at ₹132 Cr, yet trailing earnings support a P/E of 65.68. That valuation demands extraordinary future performance. Meanwhile, the company earns just 3.04% on equity and 2.68% on capital employed—figures far below what I'd expect from a business with a durable competitive advantage. Book value stands at ₹3.69, so I am paying 3.79 times net assets for a business whose latest quarter produced net profit of precisely ₹0 Cr on sales of ₹11 Cr. The 64.25% sales growth is eye-catching, but profit growth of 0.00% tells me the top-line surge is not translating into shareholder earnings. Perhaps raw material costs, competition, or heavy reinvestment are absorbing the gains. The Piotroski F-Score of 4 out of 9 reinforces my suspicion of weak financial health. With no dividend, the only potential return is price appreciation, which is speculative at these levels. In Buffett's terms, this is a business with a promising top line but a disappointing bottom line. The market appears to be pricing in a rapid turnaround, but I need evidence of margin expansion and earnings following sales before I pay such a premium. The 52-week range of ₹6.35 to ₹15.98 shows high volatility, but a low base does not make a bargain. As a value investor, I would rather watch from the sidelines than risk capital on a story where the numbers haven't yet delivered. For now, this looks like a cyclical business in an upswing, not a compounder.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer